May 17, 2024 5:35pm

Dow up, cell and gene therapy sector down having missed earnings and revenue expectations

As I had stated, "let's not forget about volatility" as algos and electronic trading flash their stuff

The Harvard Apparatus RT (OTCQB: HRGN) Chronicles: Ponzi Scheme, a Madoff look-a-life or just a Communist China rip-off?

Never leave an investor uninformed! A trusted source of factual reporting!

The week in review

The present and future value of RegMed Investors (RMi) NEWS sheds light on the stem, cell and gene therapy sector’s risks to share pricing and the sector’s upside acrobatics and potential downslides.

I write this blog/newsletter about – facts in evidence! 

 

Friday: The Dow closed UP +134.21 points or +0.34%, the S&P closed UP +6.17 points or +0.12% while the Nasdaq closed DOWN -12.35 points or -0.07%

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

The Dow closed Friday above the key 40,000 level for the first time in history.

For the week, the Dow is up 1.2%, the S&P 500 up 1.5% and the Nasdaq +2.1%.

 

RegMed Investors (RMi) - Q1/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628

 

Advance/Decline (A/D) Line:

  • Friday’s advance/decline line at the open was negative with 7 incliner, 25 decliners and 3 flats; ending with a negative close of 11 incliners, 23 decliners and 2 flats
  • Thursday’s advance/decline line at the open was negative with 9 incliner, 25 decliners and 1 flat; ending with a negative close of 13 incliners, 21 decliners and 1 flat
  • Wednesday’s advance/decline line at the open was positive with 22 incliner, 11 decliners and 2 flats; ending with a positive close of 24 incliners, 6 decliners and 5 flats
  • Tuesday’s advance/decline line at the open was positive with 26 incliner, 6 decliners and 3 flats; ending with a positive close of 19 incliners, 13 decliners and 3 flats
  • Monday’s advance/decline line at the open was positive with 30 incliner, 3 decliners and 2 flats; ending with a positive close of 22 incliners, 11 decliners and 2 flats

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:

Q2/24: 8 positive and 5 negative closes

  • April; 16 negative and 6 positive closes

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB was down -0.44% and the XBI was down -1.56%
  • Thursday, the IBB was down -0.04% and the XBI was down -0.01%
  • Wednesday, the IBB was up +1.38% and the XBI was up +2.02%
  • Tuesday, the IBB was up +0.79% and the XBI was up +1%
  • Monday, the IBB was up +0.76% and the XBI was up +2.04%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was down -0.43 point or -3.46% at 11.99
  • Thursday was up +0.01 point or +0.08% at 12.46
  • Wednesday was down -0.97 point or -7.30 % at 12.44
  • Tuesday was down -0.20 point or -1.47% at 13.40
  • Monday was up +1.04 point or +8.29% at 13.59

 

Friday’s Closing Down (10 of 22):

  • Alnylam Pharmaceuticals (ALNY -$1.82 after Thursday’s +$2.82),
  • Blueprint Medicine (BPMC -$1.68),
  • Ultragenyx Pharmaceuticals (RARE -$0.74 after Thursday’s +$1.49),
  • Verve Therapeutics (VERV -$0.40 after Thursday’s +$0.15)
  • Solid Biosciences (SLDB -$0.35 after Thursday’s -$0.39),
  • Sage Therapeutics (SAGE -$0.31 after Thursday’s +$0.30),
  • Ionis Pharmaceuticals (IONS -$0.31 after Thursday’s -$1.59, Wednesday’s +$0.94, Tuesday’s -$0.53 and Monday’s -$0.28,
  • Editas Medicine (EDIT -$0.27),
  • Fate Therapeutics (FATE -$0.24),
  • Adverum Biotechnologies (ADVM -$0.21 after Thursday’s -$0.50),

Flat (2):

  • Bellicum Pharmaceuticals (BLCM) – dropped)
  • Compass Therapeutics (CMPX $0.00 after Thursday’s +$0.06 after Wednesday’s -$0.075),

Friday’s Closing Up (11 of 11):

  • Beam Therapeutics (BEAM +$0.83 after Thursday’s -$0.32 after Wednesday’s +$0.30 after Tuesday’s -$0.21 and Monday’s +$2.76),
  • Vericel (VCEL +$0.74 after Thursday’s -$1.08 after Wednesday’s +$0.88),
  • CRISPR Therapeutics (CRSP +$0.55 after Thursday’s -$1.29, Wednesday’s +$1.25 and Tuesday’s +$0.06),
  • Agenus (AGEN +$0.36 after Thursday’s -$0.28)
  • Mesoblast (MESO +$0.33),
  • AxoGen (AXGN +$0.07),
  • Intellia Therapeutics (NTLA +$0.05),
  • Sangamo Therapeutics (SGMO +$0.04 after Thursday’s +$0.0286),
  • Prime Medicine (PRME +$0.04 after Thursday’s +$0.28),
  • Homology Medicine (FIXX +$0.0071),
  • Brainstorm Cell Therapeutics (BCLI +$0.0041 after Thursday’s +$0.032, Wednesday’s -$0.016 and Tuesday’s -$0.0479),

 

Q2/24 – May

  • Friday closed negative with 11 incliners, 22 decliners and 2 flats
  • Thursday closed negative with 13 incliners, 21 decliners and 1 flat <dropped>
  • Wednesday closed positive with 24 incliners, 6 decliners and 5 flats
  • Tuesday closed positive with 19 incliners, 13 decliners and 3 flats
  • (5/13) Monday closed positive with 22 incliners, 11 decliners and 2 flats

 

The BOTTOM LINE:  Science is thriving, but has uneven and spiraling share pricing (post earnings) while cell and gene therapies will continue to bring in value to companies; however, real growth will come when clinical outcomes and pricing of treatments catch up and get on the same page.

  • My guide to 'good news seems to be bad news' and 'bad news is good news. 'In normal times, no one really questions whether good news in the economy is actually good.

The cell and gene therapy stocks flipped negative again on Friday and Thursday after being positive – 3 sessions in a row and 8 of 13 so far this May.

  • Investors should be “playing” the cell and gene therapy sector, but not for all their invested “marbles” while share pricing is struggling for direction where economic releases are misaligned, equities get downtrodden

 

The top three (3) performing in the session:  

  • Friday: Beam Therapeutics (BEAM), Vericel (VCEL) and CRISPR Therapeutics (CRSP)
  • Thursday: Alnylam Pharmaceuticals (ALNY), Ultragenyx Pharmaceuticals (RARE) and Lenz Therapeutics (LENZ)
  • Wednesday: Blueprint Medicine (BLMC), CRISPR Therapeutics (CRSP) and Ionis Pharmaceuticals (IONS) 
  • Tuesday: BioLife Solutions (BLFS), Generation Bio (GBIO (GBIO) and Intellia Therapeutics (NTLA)
  • Monday: CRISPR Therapeutics (CRSP), Beam Therapeutics (BEAM) and Blueprint Medicine (BLMC)

The worst three (3) in the session:

  • Friday: Alnylam Pharmaceuticals (ALNY), Blueprint Medicine (BLMC) and Ultragenyx Pharmaceuticals (RARE)
  • Thursday: Ionis Pharmaceuticals (IONS), Vericel (VCEL) and CRISPR Therapeutics (CRSP)
  • Wednesday: Alnylam Pharmaceuticals (ALNY), Sage Therapeutics (SAGE) and Solid Biosciences (SLDB)
  • Tuesday: Blueprint Medicine (BLMC), Alnylam Pharmaceuticals (ALNY) and Ionis Pharmaceuticals (IONS) 
  • Monday: Solid Biosciences (SLDB), Alnylam Pharmaceuticals (ALNY) and Mesoblast (MESO)

 

BEWARE… How MANY TIMES AM I RIGHT … MORE than MOST!!

The Harvard Apparatus RT (OTCQB: HRGN) Chronicles: shows how the “pimp/pump and promote” share pricing works with WHAT news for so long …my treatise is VALIDATED!

Question, what and where is the valuation model for newest PIPE financing ?  Yet a further SCREW-JOB for early and present investors ...

April closes:

  • 5 ups, 5 downs and 11 flats

May:

  • Friday closed flat with 0 shares traded
  • Thursday closed down -$0.38 with 503 shares traded
  • Wednesday closed up +0.36 with 200 shares traded
  • Tuesday closed flat with 0 shares traded
  • (5/13) Monday closed flat with 0 shares traded
  • Friday closed up +$0.07 with 2,254 share traded
  • Thursday closed flat with 0 shares traded
  • Wednesday closed flat with 0 shares traded
  • Tuesday closed down -$0.21 with 478 shares traded
  • (5/6) Monday closed flat with 45 shares traded
  • Friday, closed up +$0.02 with 165 shares traded
  • Thursday, closed up +$0.05 with 1,444 shares traded
  • (5/1) Wednesday closed flat 0 shares traded

Question, has its major shareholder and landlord, Harvard Bioscience (HBIO) in the midst of a lay-off; been left holding a depreciating “bag” of shares (5% or 697,112 shares – SC 13G/A filing) from its $4 M share of the wrongful death lawsuit settlement having been issued 4,000 shares of series E 8% convertible Preferred stock at a price of $1,000 per share to satisfy the indemnification obligations (10-K)? 

  • How will HBIO protect itself and its asset/balance sheet with debtor OTCQB: HRGN pig with its applied lipstick and lingering odor?

Did you notice how it barely trades unless volume is being “pumped.”  

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.